Some viruses make you smell tastier to mosquitoes

Zika and dengue fever viruses alter the scent of mice and humans they infect, researchers report in the 30 June issue of Cell. The altered scent attracts mosquitoes, which bite the host, drink their infected blood and then carry the virus to its next victim.
Dengue is spread by mosquitoes in tropical areas around the world, and occasionally in subtropical areas such as the southeastern US. It causes fever, rash, and painful aches, and sometimes hemorrhage and death. More than 50 million dengue cases occur every year, and about 20,000 deaths, most of them in children, according to the National Institutes of Health (NIH) National Institute for Allergy and Infectious Disease.
Zika is another mosquito-spread viral disease in the same family as dengue. Although it is uncommon for Zika to cause serious disease in adults, a recent outbreak in South America caused serious birth defects in the unborn children of infected pregnant women. Yellow fever, Japanese encephalitis, and West Nile are also members of this virus family.
These viruses require ongoing infections in animal hosts as well as mosquitoes in order to spread. If either of these are missing — if all the susceptible hosts clear the virus, or all the mosquitoes die — the virus disappears. For example, during the yellow fever outbreak in Philadelphia in 1793, the coming of the fall frosts killed the local mosquitoes, and the outbreak ended.
In tropical climates without killing frosts, there are always mosquitoes; the virus just needs one to bite an infected host animal in order to spread. Zika and dengue viruses seem to have developed a sneaky way of increasing the odds.
A team of researchers from UConn Health, Tsinghua University in Beijing, the Institute of Infectious Diseases in Shenzhen, the Ruili Hospital of Chinese Medicine and Dai Medicine, the Yunnan Tropical and Subtropical Animal Virus Disease Laboratory, and the Chinese Center for Disease Control and Prevention, suspected that dengue and Zika might be manipulating the hosts in some way to attract mosquitoes. Both malaria and general inflammation can change people’s scent. Viral infection by dengue and Zika, they thought, might do the same thing.
First the team tested whether mosquitoes showed a preference for infected mice. And indeed, when mosquitoes were offered a choice of healthy mice or mice sick with dengue, the mosquitoes were more attracted to the dengue-infected mice.
Then they analyzed the smelly molecules on the skin of infected and healthy mice. They identified several molecules that were more common on infected animals, and tested them individually. They applied them both to clean mice, and to the hands of human volunteers, and found that one odoriferous molecule, acetophenone, was especially attractive to mosquitoes. Skin odorants collected from human dengue patients showed the same thing: more attractive to mosquitoes and more acetophenone production.
Acetophenone is made by some Bacillus bacteria that grow on human (and mouse) skin. Normally skin produces an antimicrobial peptide that keeps Bacillus populations in check. But it turns out that when mice are infected with dengue and Zika, they don’t produce as much of the antimicrobial peptide, and the Bacillus grows faster.
“The virus can manipulate the hosts’ skin microbiome to attract more mosquitoes to spread faster!” says Penghua Wang, an immunologist at UConn Health and one of the study authors. The findings could explain how mosquito viruses manage to persist for such a long time.
Wang and his coauthors also tested a potential preventative. They gave mice with dengue fever a type of vitamin A derivative, isotretinoin, known to increase the production of the skin’s antimicrobial peptide. The isotretinoin-treated mice gave off less acetophenone, reducing their attractiveness to mosquitoes and potentially reducing the risk of infecting others with the virus.
Wang says the next step is to analyze more human patients with dengue and Zika to see if the skin odor-microbiome connection is generally true in real world conditions, and to see if isotretinoin reduces acetophenone production in sick humans as well as it does in sick mice.
Story Source:
Materials provided by University of Connecticut. Original written by Kim Krieger. Note: Content may be edited for style and length.

Read more →

Winning by default: Tonsillectomy study shows power of pre-set opioid Rx size

A small tweak to hospitals’ prescribing systems might make a big difference in reducing risk from leftover opioid pain medication, while still making sure surgery patients get relief from their post-operation pain, a new study suggests.
In teens and young adults having their tonsils taken out at a major children’s hospital, patients went home with 29% fewer doses of opioid painkillers, but reported similar pain control, after researchers reduced the default opioid prescription size that doctors saw in their ordering system. Leftover doses raise the risk of long-term opioid use and the potential for misuse.
Meanwhile, prescription sizes remained high in a comparison group of young adults who had their tonsils out during the same time in nearby surgical centers that didn’t change the default prescription size. The study, from a team at Michigan Medicine, the University of Michigan’s academic medical center, is published in JAMA Network Open.
The new default prescription size — 12 doses — at U-M Health C.S. Mott Children’s Hospital was based on a survey on how many opioid doses young patients actually take for tonsillectomy pain. It replaced the previous default size of 30 doses, though doctors were always free to prescribe more or less.
After the default changed in October 2020, the percentage of patients who left the hospital with 12 doses went from 1% to 44%, the average prescription size went from 22 to 16 doses, and there was no significant change in pain control satisfaction scores or the number of prescription refills within two weeks of the operation.
Meanwhile, young adults who had their tonsils out at U-M’s University Hospital or other U-M Health surgical centers during the same time saw little change in prescribing. They received around 30 doses of opioids on average.

Read more →

The mere sight of a meal triggers an inflammatory response in the brain

Even before carbohydrates reach the bloodstream, the very sight and smell of a meal trigger the release of insulin. For the first time, researchers from the University of Basel and University Hospital Basel have shown that this insulin release depends on a short-term inflammatory response that takes place in these circumstances. In overweight individuals, however, this inflammatory response is so excessive that it can impair insulin secretion.
Even the anticipation of a forthcoming meal triggers a series of responses in the body, perhaps the most familiar of which is the watering of the mouth. But the hormone insulin, which regulates blood sugar, also arrives on the scene even before we tuck into the first mouthful of food. Experts refer to this as the neurally mediated (or cephalic) phase of insulin secretion.
Meal stimulates immune defense
In the past, however, it was unclear how the sensory perception of a meal generated a signal to the pancreas to ramp up insulin production. Now, researchers from the University of Basel and University Hospital Basel have identified an important piece of the puzzle: an inflammatory factor known as interleukin 1 beta (IL1B), which is also involved in the immune response to pathogens or in tissue damage. The team have reported their findings in the journal Cell Metabolism.
“The fact that this inflammatory factor is responsible for a considerable proportion of normal insulin secretion in healthy individuals is surprising, because it’s also involved in the development of type 2 diabetes,” explains study leader Professor Marc Donath from the Department of Biomedicine and the Clinic of Endocrinology.
Also known as “adult-onset diabetes,” this form of diabetes is caused by chronic inflammation that damages the insulin-producing cells of the pancreas, among other things. This is another situation in which IL1B plays a key role — in this case, it is produced and secreted in excessively large quantities. With this in mind, clinical studies are now examining whether inhibitors against this inflammatory factor are suitable for use as therapeutic agents for diabetes.
Short-lived inflammatory response
Circumstances are different when it comes to neurally mediated insulin secretion: “The smell and sight of a meal stimulate specific immune cells in the brain known as the microglia,” says study author Dr. Sophia Wiedemann, resident physician for internal medicine. “These cells briefly secrete IL1B, which in turn affects the autonomic nervous system via the vagus nerve.” This system then relays the signal to the site of insulin secretion — that is, the pancreas.
In the case of morbid obesity, however, this neurally mediated phase of insulin secretion is disrupted. Specifically, by the initial excessive inflammatory response, as explained by doctoral candidate Kelly Trimigliozzi, who carried out the main part of the study in collaboration with Wiedemann.
“Our results indicate that IL1B plays an important role in linking up sensory information such as the sight and smell of a meal with subsequent neurally mediated insulin secretion — and in regulating this connection,” summarizes Marc Donath.
Story Source:
Materials provided by University of Basel. Note: Content may be edited for style and length.

Read more →

Novel gene for Alzheimer's disease in women identified

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, affecting more than 5.8 million individuals in the U.S. Scientists have discovered some genetic variants that increase the risk for developing Alzheimer’s; the most well-known of these for people over the age of 65 is the APOE ε4 allele. Approximately 60 percent of people from European ancestry with Alzheimer’s carry this genetic variant, compared to just 26 percent of the general population, implying that other genes contribute to the genetic makeup of the disease.
In a new study published this week in Alzheimer’s Disease & Dementia: The Journal of the Alzheimer’s Association, researchers at the University of Chicago and Boston University School of Medicine (BUSM) have identified a new gene called MGMT that increases the risk of Alzheimer’s in women.
The researchers conducted a genome-wide association study (GWAS) for Alzheimer’s in two independent datasets using different methods. One approach focused on dementia in a large extended family of Hutterites, a founder population of central European ancestry who settled in the mid-west region of the country. Hutterites are often studied for genetic determinants of disease because they have a relatively small gene pool due to their isolated, insular culture. In this study, the individuals with Alzheimer’s were all women. The second approach, predicated on evidence suggesting a link between Alzheimer’s and breast cancer, analyzed genetic data from a national group of 10,340 women who lacked APOE ε4. In both datasets, MGMT was significantly associated with developing AD.
“This is one of a few and perhaps the strongest associations of a genetic risk factor for Alzheimer’s that is specific to women,” said Lindsay Farrer, PhD, chief of biomedical genetics at BUSM and a senior author of the study. “This finding is particularly robust because it was discovered independently in two distinct populations using different approaches. While the finding in the large dataset was most pronounced in women who don’t have APOE ε4, the Hutterite sample was too small to evaluate this pattern with any certainty.”
The researchers then further evaluated MGMT using multiple types of molecular data and other AD-related traits derived from human brain tissue. After thorough analysis, they found that that epigenetically regulated gene expression (i.e., one of the ways cells control gene activity without changing the DNA sequence) of MGMT, which has a role in repairing DNA damage, is significantly associated with the development of the hallmark AD proteins, amyloid-β and tau, especially in women.
“This study highlighted the value of founder populations for genetic mapping studies of diseases like Alzheimer’s,” said Carole Ober, PhD, Chair of Human Genetics at UChicago and a senior author of the study. “The relatively uniform environment and reduced genetic variation in Hutterites increases our power to find associations in smaller sample sizes than required for studies in the general population. The validation of our findings in the larger dataset used by the Boston University group was enormously gratifying and ultimately led to supportive epigenetic mechanisms that connected both sets of GWAS results to the MGMT gene.”
According to the researchers, this study demonstrates the importance of searching for genetic risk factors for AD that may be specific to one gender. Further studies are needed to understand why MGMT influences AD risk greater in women than men.
Story Source:
Materials provided by Boston University School of Medicine. Note: Content may be edited for style and length.

Read more →

'I never thought it would be something that I would get'

Dan has described his experience of contracting monkeypox at the start of June.He said he felt tired and nauseous before developing “blister spots” which spread across his genitals and lower body. Speaking to BBC journalist Nick Raikes, he said: “I never thought it would be something that I would get”.According to the UK Health Security Agency, there have been more than 1,000 cases of monkeypox identified in the UK since the start of May.The majority of people infected have been men who are gay, bisexual or have sex with men, with most living in London. Monkeypox is spread through close contact, such as touching skin or sharing bedding with someone who has monkeypox or has monkeypox symptoms.

Read more →

He Could Barely Walk and Had to Give Up Golf. What Was Wrong?

Over six years, many doctors told the patient he had peripheral neuropathy. What they couldn’t tell him was why — or how to treat it.It was in spring that the 69-year-old man missed playing golf the most. How he loved the cool South Carolina mornings, the feel of the club in his hands, his arms and his body moving in that perfect arc. But even before he had to stop, he noticed changes. The sensation in his fingers slowly disappeared, then their strength. He gave up the game after he nearly clobbered a friend; his club flew right out of his hands at the end of his stroke. Missed him by inches.There was so much he couldn’t do. He couldn’t open jars, couldn’t turn a doorknob. His wife got him a special tool so he could button his own shirts. He had to wear slip-on shoes. He couldn’t even cut up his own meat. He had always been independent, and each new loss felt devastating.He told his doctor about it a few years before he had to give up the game. She was concerned and sent him to a neurologist. The specialist diagnosed him with carpal-tunnel syndrome. She explained that the nerve that brings sensation from his fingers to his brain was getting squeezed as it traveled through the bony passage in his wrist called the carpal tunnel. It was an overuse injury, and rest and the use of splints usually helped. Not this time. And soon it became clear that it wasn’t just his hands. His feet began to burn, and then they, too, lost their ability to feel. Ultimately he felt as if he were walking on wooden blocks. Then his legs started to feel weak.Show Me How You WalkAs he got worse, he saw a whole lineup of specialists. More neurologists and rheumatologists — and because he had cancer 20 years earlier and radiation therapy to his neck and chest to treat it, he saw a couple of oncologists. Virtually everyone could tell him what he had: a peripheral neuropathy, a loss of nerve function in his hands and feet and, more recently, his arms and legs. But why he had it, where it came from and how it could be stopped — those essentials continued to elude them.He had tests on his blood, his urine, his nerves. After six years, he knew that there were dozens of terrible diseases he did not have. It wasn’t diabetes, H.I.V., Lyme disease or hepatitis. His thyroid was shut down by the radiation treatment that he had for his cancer, but he took thyroid hormone every day. His level was always perfect. His vitamin levels were fine.Most recently a rheumatologist tested him for every autoimmune disease he could think of, and when none of the tests were revealing, still tried a course of high-dose prednisone. If it was his immune system going wrong, then suppressing that system, which is what prednisone does, would help. When it didn’t, the doctor told him he didn’t know what more he could do. What the patient needed, at this point, were specialists at an academic medical center. They saw a wider range of disease and kept up with the newest research. He suggested a rheumatology group at the Medical University of South Carolina in Charleston, a couple of hours south. The man called them immediately but couldn’t get an appointment for months. And by then, he and his wife would be in coastal New Jersey, where they spent every summer with their grown children.Instead, he reached out to the University of Pennsylvania Health System in Philadelphia. It was just an hour away from their beach house, and he got a pacemaker there a few years earlier. A single call got him a telehealth appointment with a Penn neurologist the following week, from his home in North Myrtle Beach, S.C.After the patient signed on for his video visit, Dr. Mariam Saleeb listened carefully as he recounted the activities he can no longer pursue and his worsening weakness and disability. He could hardly walk, and he’d lost nearly 40 pounds over the past few years. He was only 69 but felt like an old man. Saleeb asked him to get up and show her how he walked. He leaned forward and used his arms to push himself to an upright position.Even on the video, Saleeb could see that the patient’s hands were almost skeletal, as if the fat and muscle had simply melted away. His arms were also much thinner than she would expect from his build. His walk was awkward, his legs splayed far beyond the width of his hips, giving his movement a Frankenstein’s-monster quality, and he couldn’t lift the toes on his right foot, so it dragged as he walked. She needed to do some additional testing. When could he come to her office? Soon, he told her. They were traveling north in six weeks.When she finally saw the patient, Saleeb noted that the man was even thinner than he looked on the video visit. And he had almost no feeling in his legs. When she pricked him with the point of a safety pin, he didn’t even blink until she got above the knees. His hands were almost as bad. And he was right — he was very weak. She tested the nerves in his arms and legs by shooting tiny pulses of electricity to one nerve and measuring the strength of the signal and how long it took to get from one point to another. There was almost no signal getting from his lower legs to his feet, and just a trace from his hands to his arms.There are hundreds of possible causes of peripheral neuropathy. Diabetes is probably the most common. Alcohol abuse can do it. So can too little vitamin B12 or too much vitamin B6. Several drugs can cause this kind of neuropathy, as well as some toxins. Autoimmune diseases and inherited diseases can too.Most peripheral neuropathies affect sensation first. He had what was called a stocking-and-glove neuropathy: one that starts in the feet and moves upward to the hands and keeps going. Most of the time, the feet and hands burn and sting as if they were being stuck with pins and needles, and then slowly, usually over years, sensation dies. But this kind of rapidly progressive and profound sensory loss combined with weakness was a red flag. Saleeb wasn’t sure what he had, but she was certain that he needed to see someone even more specialized and referred him to the clinic that focused on neuromuscular disease.Photo illustration by Ina JangA Special TestDr. Margaret Means was the first doctor to express confidence that a diagnosis could be found. After her exam, she said, “You’ve really had a lot on your plate, but I know we are going to get to the bottom of this.” Then she disappeared. Ten minutes later she returned with a tall man dressed in scrubs whom she introduced as Dr. Chafic Karam.Karam asked a few questions and reviewed the records the patient had brought. After a brief examination, he told the patient that they would send him to the lab for more blood work, but first they wanted to take a biopsy of the subcutaneous fat on his abdomen to look for a condition known as amyloidosis. In this disorder, the liver creates abnormal proteins that form fibers that circulate throughout the body, invading organs and nerves and even the fat and skin. These fibers interfere with the body’s normal function just by being there. They are one cause of peripheral neuropathy.Two weeks later Karam called with the results. What he had, Karam explained, was very rare, with maybe 10,000 cases in the entire world. It was a type of amyloidosis caused by a genetic abnormality that he inherited from one of his parents. And this abnormality was the cause of many of his medical problems. It was why he needed a pacemaker — because the fibers had interfered with his heart’s ability to regulate its rhythm. It was why he was losing weight. His digestive system had trouble absorbing the nutrients he ate. And it was certainly why he had this debilitating neuropathy. The patient thought about his parents, both dead for many years. Both had many health problems, but he had no idea which one might have had this amyloidosis.His children were at risk, Karam told him: There was a 50-50 chance that he had passed this abnormal gene on to them. None of his children have yet gotten tested, and the patient is worried about what they might find. Still, there are new medications that can slow this process, though they can’t repair the damage already done. The patient is now on two of these drugs, and the deterioration of his physical abilities has stopped. He can still walk, albeit slowly. And he has accepted the fact that he will never play golf again. These days, somehow it’s enough just to watch.Lisa Sanders, M.D., is a contributing writer for the magazine. Her latest book is “Diagnosis: Solving the Most Baffling Medical Mysteries.” If you have a solved case to share, write her at Lisa.Sandersmdnyt@gmail.com.

Read more →

Invisible disabilities: How an autism diagnosis changed my life

What’s it like living with an invisible disability in London? In the UK one in 100 people are on the autism spectrum and there are around 700,000 autistic adults and children. (Source: National Autistic Society)Barrington Campbell received an autism diagnosis at 30 years old. He said he had struggles making friends while growing up and felt isolated.Five years later he’s created Kagai Games, designed to provide tabletop games and events for people with social anxiety. He said: “I wanted to provide a space that was inclusive for everyone with social anxiety.”Video by Gem O’Reilly

Read more →

Road injuries are killing young people, and it's hardly slowing down

New research led by UNSW Sydney reveals traffic-related fatalities and injuries are the biggest killers of young people worldwide – causing more deaths than communicable and non-communicable diseases or self-harm. The findings are published todayin The Lancet Public Health in thefirst global analysis of transport and unintended injury-related morbidity and mortality of young people aged 10-24.
Using the latest data from the Global Burden of Disease (GBD) 2019 Study, the researchers analysed deaths and Disability-Adjusted Life Years (DALYs) from transport and unintentional injuries in adolescents across 204 countries in the past three decades. They found that despite transport injury death rates falling by a third since 1990, the number of deaths attributed to road fatalities for adolescents still increased in some countries.
“We’ve seen a high increase in the absolute number of injury-related deaths and DALYs, specifically in low and low-middle income countries. It indicates neglect for a growing population at risk of injury,” says lead author Dr Amy Peden, research fellow with the School of Population Health at UNSW Medicine & Health.
Prevention progress stalling
According to the research, reductions in transport injury and death rates in high-income countries have slowed in the most recent decade. They dropped just 1.7 per cent a year between 2010 and 2019 compared to the fall of 2.4 per cent a year between 1990 and 2010.
“In high-income countries like Australia, there’s been a real decline in progress. In the past 10 years, we’ve seen reductions in rates of road transport injury essentially stall, showing a lack of attention to the issue,” Dr Peden says.

Read more →

Up to 540,000 lives could be saved worldwide by targeting speed and other main areas

A new series published in The Lancet today highlights the growing problem of road traffic injuries and lays out some opportunities for preventing injuries and saving lives. The series comes at the same time as the United Nations General Assembly launches a high-level meeting on global road safety June 30-July 1 in New York. The series offers a comprehensive analysis of this rising public health threat.
An estimated 1.35 million people lose their lives and more than 50 million are injured or disabled as a result of road traffic injuries every year. “The death toll from traffic injuries around the world is far too high,” Adnan Hyder, professor of global health at the George Washington University Milken Institute School of Public Health, said. “Despite a United Nations goal to reduce this heavy burden, people everywhere continue to be at great risk of injury and death unless current road traffic strategies are changed to put protections in place.”
Hyder, who is Senior Associate Dean for Research and also the Director of the Center on Commercial Determinants of Health at the GW Milken Institute School of Public Health, serves as the lead author of an analytic commentary and is the senior author on two other papers published as part of the three-part series.The analytic commentary reviews events that occurred from 1999 to the present and describes ten challenges that provide an opportunity to make faster progress on road safety.
Two other papers in the series address the issue of road safety around the world. In the first, Junaid Razzak at the Weill Cornell Medical Center, Hyder and their colleagues looked at trauma care for road injuries. They found that approximately 200,000 lives per year could be saved with improved trauma systems in low and middle income countries.
In the second paper, Hyder, Nino Paichadze from GW, Andres Vecino-Ortiz at the Johns Hopkins University and their colleagues studied four road safety risk factors-speed, drunk driving, helmet and seatbelt use. They found that full implementation of already proven road safety interventions targeting those four main areas could save up to 540,000 lives around the world.
In the United States, a total of about 43,000 lives could be saved by focusing on those four road safety areas, including more than 22,000 lives saved by restricting speed and more than 5100 with interventions on drunk driving. Another 14,000 and 2400 lives could be saved with better use of seatbelts and helmets, respectively.
In the analytic commentary, Hyder and his colleagues outline some of the pitfalls that must be overcome to make the roadways safer. They point out that road safety involves many sectors, including health, transportation and other areas; and suggest addressing commercial determinants of road safety. To address road safety the roles of each sector must be clear and one sector should take the lead on developing a strategy, Hyder said.
Finally, the authors recommend reframing road safety so that the issue resonates with the public and political leaders. At the same time, there must be the political will to put enough resources toward this problem to address it, Hyder said.
Articles in the Lancet: https://www.thelancet.com/series/road-safety
Story Source:
Materials provided by George Washington University. Note: Content may be edited for style and length.

Read more →

Behind the Scenes, McKinsey Guided Companies at the Center of the Opioid Crisis

Behind the Scenes, McKinsey Guided Companies at the Center of the Opioid Crisis

#27-mack-top {
max-width: 100% !important;
}

header svg {
fill: #121212 !important;
}

#link-78f0544a {
display: none;
}

#headline {
display: flex;
font-family: ‘nyt-cheltenham’;
font-weight: 700;
font-style: italic;
font-size: 26px;
line-height: 29px;
text-align: center;
max-width: 940px;
margin: auto;
margin-bottom: 60px;

-webkit-font-smoothing: antialiased;
-moz-osx-font-smoothing: grayscale;
}

.NYTApp #headline {
width: calc(100% – 40px);
}

#top-wrapper {
display: flex;
width: 100%;
height: 100vh;

flex-direction: column;

}

.image-wrapper {
display: flex;
margin: auto;
max-width: 610px;
margin-top: 0;
}

@media (min-width: 940px) {
#top-wrapper {
min-height: 900px;
}

#headline {
font-size: 55px;
line-height: 60px;
margin-bottom: auto;
}
}

Supported byContinue reading the main storyBehind the Scenes, McKinsey Guided Companies at the Center of the Opioid CrisisThe consulting firm offered clients “in-depth experience in narcotics,” from poppy fields to pills more powerful than Purdue’s OxyContin.Send any friend a storyAs a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.Chris Hamby and The reporters pored over a trove of more than 100,000 documents to investigate McKinsey’s unknown work for opioid makers.June 29, 2022, 6:15 p.m. ETIn patches of rural Appalachia and the Rust Belt, health authorities were sounding alarms that a powerful painkiller called Opana had become the drug of choice among people abusing prescription pills.It was twice as potent as OxyContin, the painkiller widely blamed for sparking the opioid crisis, and was relatively easy to dissolve and inject. By 2015, government investigations and scientific publications had linked its misuse to clusters of disease, including a rare and life-threatening blood disorder and an H.I.V. outbreak in Indiana.Opana’s manufacturer, the pharmaceutical company Endo, had scaled back promotion of the drug. But months later, the company abruptly changed course, refocusing resources on the drug by assigning more sales representatives.The push was known internally as the “Sales Force Blitz” — and it was conducted with consultants at McKinsey & Company, who had been hired by Endo to provide marketing advice about its chronic-pain medicines and other products.

.document-tear {
width: 100%;
margin: auto;
margin-bottom: 40px;
margin-top: 30px;
padding-top: 20px;
padding-bottom: 20px;
border: 0.0px solid #d3d0d0;
max-width: 600px;
box-shadow: 0px 1px 5px -1px #afa8a8;
}

.document-tear.doc-img {
margin-bottom: 15px;
}

.document-tear u {
text-decoration: none;
background-color: #FFF8B9;
padding-top: 1.5px;
padding-bottom: 1.5px;
}

.document-tear strong {
text-decoration: none;
background-color: #121212;
padding-top: 1.5px;
padding-bottom: 1.5px;
color: #121212
}

.document-tear h4 {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
font-weight: 800;
font-size: 13px;
margin-bottom: 15px;
text-transform: uppercase;
padding-bottom: 10px;
border-bottom: 1px solid;
}

.document-tear p {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
font-weight: 200;
font-size: 18px;
line-height: 26px;
}

.document-tear a {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
display: inline-block;
font-weight: 500;
font-size: 14px;
text-align: right;
color: #326891;
text-decoration: underline;
}

.document-tear img {

width: calc(100% – 40px);
margin: auto;
display: block;
}

.doc-caption {
font-size: 0.875rem;
line-height: 1.125rem;
font-family: ‘nyt-imperial’;
color: #727272;
max-width: 600px;
margin: auto;
margin-bottom: 40px;
}

@media (min-width: 740px) {
font-size: 0.9375rem;
line-height: 1.25rem;
}

McKinsey Settlement Documents

A campaign by McKinsey and Endo to push the company’s chronic-pain products, including Opana.The untold story of McKinsey’s work for Endo was among the revelations found by The New York Times in a repository of more than 100,000 documents obtained by a coalition of state attorneys general in a legal settlement related to McKinsey’s opioid work.Much has been disclosed over the years about McKinsey’s relationship with Purdue Pharma, including the consulting firm’s recommendation that the drug maker “turbocharge” its sales of OxyContin. But The Times found that the firm played a far deeper and broader role in advising clients involved in the opioid crisis than was publicly disclosed.The McKinsey records include more than 15 years of emails, slide presentations, spreadsheets, proposals and other documents. They provide a sweeping and detailed depiction of a firm that became a trusted adviser to companies at the core of an epidemic that has claimed half a million American lives.While the firm held remarkable sway at Purdue, it also advised the largest manufacturer of generic opioids, Mallinckrodt. It worked with Endo on marketing Opana and helped it grow into a leading generics manufacturer. It advised Johnson & Johnson, whose subsidiary Tasmanian Alkaloids was the largest supplier of the raw materials extracted from poppies used to make many top-selling opioids. Then, as the full brunt of the epidemic became apparent, it counseled government agencies on how to address the fallout.McKinsey’s opioid clients already wanted to grow their businesses. What the firm offered was know-how and sophistication, the documents show, and, as it noted in one presentation, “in-depth experience in narcotics.”The Massachusetts attorney general, Maura Healey, who helped craft the settlement, said in a statement that “as Americans were dying from the opioid epidemic, McKinsey was trading on its reputation and connections to make the crisis worse.” She added that the newly released documents “expose McKinsey’s role in the opioid crisis and will inform policymakers’ efforts to prevent this from happening again.”Drawing on reams of data and proprietary tools, McKinsey vetted deals and advised on corporate strategy. It developed tactics for dealing with regulators and helped secure approval for new products.The firm helped clients adopt more aggressive sales strategies, which, on at least two occasions, led companies to shift resources to more potent products. It profiled and targeted physicians, in some instances trying to influence prescribing habits in ways that federal officials later warned heightened the risk of overdose.And when opioid prescriptions began to decrease during a government crackdown, the records show, McKinsey devised new approaches to drive sales.McKinsey agreed to provide the documents to the attorneys general last year as part of a nearly $600 million settlement in which it admitted no wrongdoing. The firm has since apologized for its advice to opioid makers but, in a statement on Wednesday, suggested that its work with companies other than Purdue was “much more limited” and that it “did not counsel or recommend to Endo that it promote Opana more aggressively.”“We recognize the terrible consequences of the opioid epidemic and have acknowledged our role in serving opioid manufacturers,” said a McKinsey spokesman. “We stopped that work in 2019, have apologized for it and have been focused on being part of the solution.”An Endo spokeswoman declined to comment on the company’s work with McKinsey, citing litigation. She instead referred to a company statement saying that in September 2016 Endo had “stopped promoting opioid products to health care professionals” and eliminated its opioid-focused sales force.Mallinckrodt declined to comment. Johnson & Johnson, in a statement, maintained that all its actions were appropriate, while Purdue said that it was focused on ending bankruptcy proceedings so it could reorganize into a new, more “public-minded” company that would “deliver billions of dollars of value” toward abating the opioid crisis and compensating victims.‘Opana Patients’Dr. Steven Butler, a kidney specialist serving a largely rural stretch of East Tennessee, helped with an unusual case in fall 2012. A woman in her 20s had arrived at the Holston Valley Medical Center in Kingsport with an array of symptoms — she was anemic, and her kidneys appeared to be failing — that resembled a rare blood disorder.A few days later, another patient with similar symptoms arrived at the hospital. Then a third. Dr. Butler called the Tennessee Department of Health, which launched an investigation. Over the following months, more patients appeared.As they underwent time-consuming treatments, some acknowledged they had dissolved and injected a pill whose name Dr. Butler had never heard before: Opana ER.The Opioid CrisisFrom powerful pharmaceuticals to illegally made synthetics, opioids are fueling a deadly drug crisis in America.An Unrelenting Surge: ​​Deaths from drug overdoses again rose to record-breaking levels in 2021. Here is how to talk to your family about the threat opioids pose.Youth Deaths: Young people are turning to social media to find prescription pills. But drugs found this way are often laced with deadly doses of fentanyl.A Settlement: Purdue Pharma reached a deal with a group of states that long resisted the structure of the original bankruptcy plan. Here is what the agreement means.Detailing Tragedies: As part of the settlement, families who lost loved ones to opioid addiction were allowed to address the owners of Purdue Pharma in court.“Locally, it became a very well-described phenomenon,” he recalled. “They were just called ‘Opana patients,’ as though that was a real common thing.”The tangled path that led to Opana’s rise illustrates McKinsey’s deep involvement in the opioid business, with its work for one client rippling out with consequences for others.Years earlier, the firm had helped usher the drug onto the market, advising Endo’s partner, Penwest Pharmaceuticals, on its launch in 2006. Two years later, the documents show, McKinsey performed a project for Purdue that paved the way for Endo to extend Opana’s reach.Purdue was seeking approval from the Food and Drug Administration for a new version of OxyContin that would be more difficult to snort or inject. After the F.D.A. denied its application in 2008, Purdue enlisted McKinsey’s help. The consultants interviewed a former drug dealer about OxyContin abuse, oversaw scientific studies, prepared regulatory documents and coached company officials on how to deal with the F.D.A., which had been a McKinsey client. The agency gave its approval in 2010, and later allowed Purdue to claim the new pills were resistant to abuse.Soon, OxyContin sales declined — while Opana sales rose. In an internal document, Endo attributed the uptick in part to “patient dissatisfaction with new OxyContin formulation.” Data on abuse showed similar trends: a decline for OxyContin and a rise for Opana.Endo later developed a new version of Opana it wanted to promote as abuse-resistant. The F.D.A. found that the new pills “demonstrated a minimal improvement in resistance to tampering by crushing,” and that they were “readily abusable” by injection. The agency allowed the drug to enter the market in early 2012, but without being labeled as resistant to abuse.Cooking Opana in order to inject it, on a stove in West Virginia.Mark TrentWithin months, Dr. Butler saw his first Opana patient. In October 2012, both the F.D.A. and the Centers for Disease Control and Prevention put out health alerts about the blood syndrome. Then another cluster appeared, in North Carolina, and other cases in Arkansas, Florida, Pennsylvania and South Carolina.To make matters worse, according to the F.D.A., the new version of Opana drove many users to switch from snorting to injecting, considered a riskier form of abuse. The likely cause of the blood disorder, researchers determined, was the very substance that Endo had added to make the pills harder to crush. When dissolved and injected, it could trigger rapid red blood cell destruction and organ damage.Rajiv De Silva, formerly of McKinsey, took over Opana’s manufacturer, Endo, in 2013.BusinesswireAs concerns about Opana grew, Endo hired a new chief executive in 2013: Rajiv De Silva, a former leader within McKinsey’s pharmaceutical practice who soon tapped the firm to help chart a growth strategy.A few months after Mr. De Silva took over, McKinsey helped Endo execute a complicated maneuver known as a “tax inversion” — a legal form of tax avoidance that the Obama administration would decry as an “abuse” of the system. For tax purposes, the Pennsylvania company was now based in Ireland, where the rate was substantially lower.Endo’s offices in Dublin. With the help of McKinsey, it moved its headquarters out of the U.S. for tax purposes.Paulo Nunes dos Santos for The New York TimesThe move, which sent Endo’s stock price climbing, was “a tax play to set up doing a lot of deals,” according to a 2014 email from a McKinsey partner named Dr. Arnab Ghatak, who also helped lead the firm’s work with Purdue.Endo went on a buying spree and would soon become one of the largest U.S. manufacturers of generic opioids.‘The Narcotics Franchise’The production of pills by companies like Endo and Purdue depended on a complex and tightly regulated global supply chain stretching from the fields of Tasmania to factories in the American heartland.Here, too, was McKinsey.Long before a patient in the United States filled a prescription for OxyContin, a farmer on another continent harvested a poppy rich in a substance called thebaine. Tasmanian Alkaloids, the Johnson & Johnson subsidiary, controlled the majority of this market.From far-flung fields and extraction facilities, the raw materials made their way to American processing plants. The top U.S. producers at this stage were another Johnson & Johnson subsidiary, Noramco, and Mallinckrodt, the big generics manufacturer.The documents reveal McKinsey’s work advising them behind the scenes. By the firm’s own account, it had deep expertise in the international trade of legal narcotics. “We serve the majority of the leading players,” the consultants wrote in a 2009 memo.That year, the firm oversaw a project for Johnson & Johnson titled “Maximizing the Value of the Narcotics Franchise.” In a presentation set against an image of a poppy field, the consultants advised the company on how it could invest to further strengthen its already-dominant position or sell the business if the price was right.

.document-tear {
width: 100%;
margin: auto;
margin-bottom: 40px;
margin-top: 30px;
padding-top: 20px;
padding-bottom: 20px;
border: 0.0px solid #d3d0d0;
max-width: 600px;
box-shadow: 0px 1px 5px -1px #afa8a8;
}

.document-tear.doc-img {
margin-bottom: 15px;
}

.document-tear u {
text-decoration: none;
background-color: #FFF8B9;
padding-top: 1.5px;
padding-bottom: 1.5px;
}

.document-tear strong {
text-decoration: none;
background-color: #121212;
padding-top: 1.5px;
padding-bottom: 1.5px;
color: #121212
}

.document-tear h4 {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
font-weight: 800;
font-size: 13px;
margin-bottom: 15px;
text-transform: uppercase;
padding-bottom: 10px;
border-bottom: 1px solid;
}

.document-tear p {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
font-weight: 200;
font-size: 18px;
line-height: 26px;
}

.document-tear a {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
display: inline-block;
font-weight: 500;
font-size: 14px;
text-align: right;
color: #326891;
text-decoration: underline;
}

.document-tear img {

width: calc(100% – 40px);
margin: auto;
display: block;
}

.doc-caption {
font-size: 0.875rem;
line-height: 1.125rem;
font-family: ‘nyt-imperial’;
color: #727272;
max-width: 600px;
margin: auto;
margin-bottom: 40px;
}

@media (min-width: 740px) {
font-size: 0.9375rem;
line-height: 1.25rem;
}

McKinsey Settlement Documents

A presentation McKinsey prepared for Johnson & Johnson, whose subsidiaries played key roles in the opioid supply chain.For Mallinckrodt, McKinsey consultants walked factory floors and monitored production data, recommending how the company might coax greater yields from the same base of raw materials and speed up manufacturing lines.In 2016, McKinsey prepared Mallinckrodt for negotiations with companies that sourced generic drugs for Walmart and CVS, and advised on dealing with the Drug Enforcement Administration. The D.E.A. had set production limits to prevent an oversupply of pills, and McKinsey counseled Mallinckrodt on how it could use logistical tactics to secure a higher quota while maintaining a “friendly relationship” with the agency.“To suggest this work was intended to undermine relevant laws or regulations would be false,” the McKinsey spokesman said.McKinsey consultants also took jobs at the opioid manufacturers themselves. A partner in the firm’s pharmaceutical practice, Frank Scholz, became Mallinckrodt’s senior vice president of global operations in 2014 and later was promoted to president of its generics business.But it was the arrival of Mr. De Silva at Endo that brought a particular opportunity for McKinsey. In late 2014, the company asked the consultants to provide advice on structuring the company’s sales force. This soon evolved into a more detailed project in an area where McKinsey excelled: how to dispatch hundreds of sales representatives to maximum effect.Shifting to OffenseMcKinsey had a playbook for seemingly any problem a pharmaceutical company might face, from production snags to generic competition to inquisitive regulators. But the firm had a particular penchant for sales and marketing.In the years leading up to its work on Opana, McKinsey had built increasingly powerful tools for getting the right messages in front of the right physicians, and the firm had honed them in numerous opioid-marketing projects, including two for Johnson & Johnson.While the broad strokes of these efforts have been known, the documents provide an unprecedented look inside McKinsey’s tool kit. The records related to the firm’s work for Purdue are particularly detailed, providing insight into the strategies that consultants used for other companies.In 2009, the firm recommended a technique known as segmentation. The best marketing campaigns — whether for food, cars or electronics — divided consumers into segments based on how they acted and thought, then developed tailored messages to win them over, the consultants said.In Purdue’s case, the customer was a physician with a license to prescribe controlled substances, and the product was OxyContin.The consultants interviewed dozens of physicians and solicited the views of hundreds more in a survey. Four groups of doctors emerged, each with a distinct profile. The consultants then developed messages to appeal to each group’s practical and emotional needs.

.document-tear {
width: 100%;
margin: auto;
margin-bottom: 40px;
margin-top: 30px;
padding-top: 20px;
padding-bottom: 20px;
border: 0.0px solid #d3d0d0;
max-width: 600px;
box-shadow: 0px 1px 5px -1px #afa8a8;
}

.document-tear.doc-img {
margin-bottom: 15px;
}

.document-tear u {
text-decoration: none;
background-color: #FFF8B9;
padding-top: 1.5px;
padding-bottom: 1.5px;
}

.document-tear strong {
text-decoration: none;
background-color: #121212;
padding-top: 1.5px;
padding-bottom: 1.5px;
color: #121212
}

.document-tear h4 {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
font-weight: 800;
font-size: 13px;
margin-bottom: 15px;
text-transform: uppercase;
padding-bottom: 10px;
border-bottom: 1px solid;
}

.document-tear p {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
font-weight: 200;
font-size: 18px;
line-height: 26px;
}

.document-tear a {
width: calc(100% – 40px);
font-family: ‘nyt-franklin’;
margin: auto;
display: inline-block;
font-weight: 500;
font-size: 14px;
text-align: right;
color: #326891;
text-decoration: underline;
}

.document-tear img {

width: calc(100% – 40px);
margin: auto;
display: block;
}

.doc-caption {
font-size: 0.875rem;
line-height: 1.125rem;
font-family: ‘nyt-imperial’;
color: #727272;
max-width: 600px;
margin: auto;
margin-bottom: 40px;
}

@media (min-width: 740px) {
font-size: 0.9375rem;
line-height: 1.25rem;
}

McKinsey Settlement Documents

McKinsey, drawing on data analyses, made personality profiles of doctors to fuel opioid sales.McKinsey identified a particular opportunity in doctors who were hesitant to prescribe OxyContin because of worries about abuse, addiction and possible scrutiny from the D.E.A. These physicians often tried to treat chronic pain with less powerful drugs.Persuading them to switch to OxyContin could be worth hundreds of millions of dollars, McKinsey advised. To do this, McKinsey proposed tactics to “raise physician comfort levels through appropriate education and support.” Sales representatives, McKinsey said, should reassure doctors that many of their colleagues prescribed OxyContin and that the drug need not be reserved for extreme pain.In 2014, the F.D.A. introduced new labeling requirements for OxyContin and similar opioids, limiting their use to cases of severe chronic pain in which less risky treatments had proved ineffective. But McKinsey’s strategy had long since been rolled out.Another McKinsey approach, known as targeting, tried to identify doctors who would provide the greatest return on sales representatives’ time.Purdue, dissatisfied with dipping OxyContin sales in 2013, had enlisted McKinsey’s help. Revenues were down, the consultants advised, in large part because of government actions to tamp down the opioid epidemic. Doctors were writing prescriptions for fewer tablets and lower doses, and wholesalers and pharmacies were imposing new controls.Fentanyl Overdoses: What to KnowCard 1 of 5Devastating losses.

Read more →